News
HSBC and Axis Capital are more bullish on its transformative impact and future growth prospects for Glenmark, while Nuvama ...
7h
Zacks Investment Research on MSNAbbVie (ABBV) Laps the Stock Market: Here's WhyAbbVie (ABBV) closed the most recent trading day at $195.00, moving +2.3% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.28%. On the other hand, the Dow registered ...
This was the stock's third consecutive day of gains.
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...
TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial ...
13h
InvestorsHub on MSNAbbVie Shares Climb on $700 Million Licensing Deal with IGI TherapeuticsAbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing ...
Analysts have provided new insights into AbbVie and Esperion, two major players in the healthcare sector. AbbVie’s stock has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results